Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I. Murakami R, et al. Among authors: tanabe h. Gynecol Oncol. 2019 May;153(2):312-319. doi: 10.1016/j.ygyno.2019.02.010. Epub 2019 Mar 8. Gynecol Oncol. 2019. PMID: 30853361 Clinical Trial.
Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, Shimizu C, Ando M, Kamura T, Kasamatsu T, Fujiwara Y. Nishio S, et al. Among authors: tanabe h. J Cancer Res Clin Oncol. 2009 Apr;135(4):551-7. doi: 10.1007/s00432-008-0488-x. Epub 2008 Oct 1. J Cancer Res Clin Oncol. 2009. PMID: 18830625
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K, Nagata C, Yanaihara N, Tanabe H, Okamoto A. Suzuki K, et al. Among authors: tanabe h. Int J Gynecol Cancer. 2014 Sep;24(7):1181-9. doi: 10.1097/IGC.0000000000000178. Int J Gynecol Cancer. 2014. PMID: 25010038
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.
Okamoto A, Sehouli J, Yanaihara N, Hirata Y, Braicu I, Kim BG, Takakura S, Saito M, Yanagida S, Takenaka M, Yamaguchi N, Morikawa A, Tanabe H, Yamada K, Yoshihara K, Enomoto T, Itamochi H, Kigawa J, Matsumura N, Konishi I, Aida S, Aoki Y, Ishii N, Ochiai K, Akiyama T, Urashima M. Okamoto A, et al. Among authors: tanabe h. PLoS One. 2015 Feb 6;10(2):e0116977. doi: 10.1371/journal.pone.0116977. eCollection 2015. PLoS One. 2015. PMID: 25658832 Free PMC article.
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S, Nishio S, Okada S, Otsuki T, Fujiwara K, Tanabe H, Takano M, Hasumi Y, Takei Y, Hasegawa T, Matsumoto T, Fujiwara K, Takekuma M, Nakamura K, Shimada M, Suzuki M, Kigawa J. Nagao S, et al. Among authors: tanabe h. Cancer Chemother Pharmacol. 2015 Aug;76(2):335-42. doi: 10.1007/s00280-015-2793-9. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092322
1,244 results